C-suite Executive with extensive international pharmaceutical and medical devices expertise in leading companies’ business expansion, with an ability to communicate in Spanish, English and German. Worked at top global corporations such as GE Healthcare in the United States and the BMW Group in Germany. Results oriented cross-functional leader with proven abilities in strategic and tactical planning, operational efficiency, driving market growth and delivering results. Motivational management style with a solid experience working in a matrix environment with diverse multicultural teams.
Corporate Director Partner
Cristian Fabbri is one of the founding directors of Qualix Ventures - parent Company of Qualix Pharma and Qualix DoT. He has extensive international pharmaceutical expertise participating for more than 15 years in the Industry with leading roles in the areas of marketing, business development and strategic management. Cristian has worked in the banking industry at Banco Galicia Buenos Aires and also in the food chain business at Farm Frites Argentina. Hen is member of the Investment committee at GridX, a company builder fund in the Latam biotech arena, and also member of the Argentina Chamber of Biotech. He is also engaged as an angel investor in the tech and biotech fields. His academic background includes an Economics degree at Universidad Torcuato Di Tella and a fast track MBA from Hult Arthur D Little Business School in Boston.
Emeritus Professor of Musculoskeletal Pharmacology
Graham Russell is Emeritus Professor of Musculoskeletal Pharmacology at The Botnar Research Centre, a research centre at the University of Oxford.
Graham Russell's fundamental discoveries on calcium and bone metabolism ushered in the bisphosphonates — drugs now used worldwide to protect bones in age-related diseases such as osteoporosis, and also in Paget's disease, myeloma and bone cancers. He has since elucidated the action of these drugs, and used his insights to design new uses for these and other agents.
Graham's work has clarified the biochemical pathways by which calcification is regulated, and how bones are continually broken down and reconstructed during life. By mimicking naturally occurring molecules, bisphosphonates intervene in these process and prevent diseased bone from being lost faster than it can be replaced.
Honorary President of the Paget's Association, Graham has held many other positions in charitable and scientific organisations. He was the first British recipient of two senior awards from the American Society for Bone and Mineral Research — their major scientific award, the William F. Neuman Award in 2000, and the Gideon A. Rodan Excellence in Mentorship Award in 2014 for the support he has given to young investigators in the field.
Professor of Medicine at the LeidenCenter for Bone Metabolism
Socrates Papapoulos is Emeritus Professor in Diseases of Bone and Mineral Metabolism at the Leiden University Medical Center, the Netherlands. He was trained in Internal Medicine and Endocrinology in Athens, GR and London, UK and since 1974 has been continuously engaged in basic and clinical research, patient care and teaching. He has served on numerous boards and committees including the Board and the Scientific Advisory Board of the IOF, the Board of Directors of the ECTS and the IBMS and the European Union committee for the prevention of osteoporosis.
A former Director of Bone and Mineral Research at the Leiden University Medical Center and President of the Dutch Society for Calcium and Bone Metabolism, Dr Papapoulos is recipient of the Boy Frame Memorial Award and the Frederic C Bartter Award of the ASBMR, the John Haddad Jr Award of the IBMS, the JB Johnson Award of the Paget’s Foundation, USA, the Steven Boonen Award of ECTS , the Pierre Delmas Award of the IOF and he is Doctor Honoris Causa of the Universities of Athens and Thessaloniki. His past and present editorial duties include Bone and Mineral, Bone, BONEKey, Clinical Endocrinology, Endocrine, Expert Reviews Endocrinology and Metabolism, Nature Reviews Endocrinology, Osteoporosis International, Osteoporosis Reports. For his societal and scientific contributions, Dr Papapoulos was awarded the distinctions of Commander of the Order of the Phoenix and Officer of the Order of Oranje-Nassau, by the President of the Greek Republic and the Queen of the Netherlands, respectively.
Corporate Financial Controller
Ezequiel is the Corporate Financial Controller of Qualix Ventures, where he is responsible for the finance and administration for the overall companies of the group. Prior to his current role, he has gained experience in financial strategic roles in the pharmaceutical industry and in one of the Big Four largest accounting firms. He is an Assistant Professor at the University of Buenos Aires. Ezequiel is certified as a Public Accountant and holds an Executive MBA degree.
Project Leader at Qualix Dot
Marcos Mosteirin is a Project Leader at Qualix DoT, where he is responsible for the project portfolio management. Prior to his current role, he gained significant experience in operational and strategic roles in the pharmaceutical and in the construction industries working for prestigious companies such as Merck & Co. and Techint Group. Marcos is an industrial engineer and holds a Project Management Professional certification from Project Management Institute (PMI).
Dr. Emilio Roldán
Corporate Scientific Director
Emilio is the Corporate Scientific Director of Qualix DoT. Prior to his current role, he has work in the pharmaceutical industry for more than 40 years where he was responsible for driving research towards the development of novel and effective therapies. He has published more than 200 scientific papers, generated invention patents and received national and international awards.
He holds a M.D. degree from University of Buenos Aires (UBA), a master in Clinical Pharmacology (UBA) and a Ph.D. (UBA, honored with the “Faculty of Medicine Best Thesis Award”). He developed scientific activities in the Faculty of Pharmacy and Biochemistry (UBA) and the Institute of Metabolic Research (IDIM).
He was elected as member of the board of ICORD - International Conference on Rare Diseases & Orphan Drugs- an international NGO based at Barcelona (Spain) devoted to rare diseases and orphan drugs. ICORD seeks for collaboration among academy, industry, patient´s organizations and government’s interest. He is also a co-opted member, since 2017 of IOF International Osteoporosis Foundation focusing on Skeletal Rare Diseases Chapter. He also served on scientific committees of several world and regional congresses on rare diseases and orphan drugs.